奥沙利铂联合表柔比星介入治疗原发性肝癌的临床疗效分析  

Clinical Efficacy Analysis of Oxaliplatin Combined with Epirubicin Intervention in the Treatment of Primary Hepatocellular Carcinoma

作　　者：陈健[1] 姜成毅 王艳梅[3] 孙志强[2] CHEN Jian;JIANG Chengyi;WANG Yanmei;SUN Zhiqiang(Interventional Department,Jilin Provincial Cancer Hospital,Changchun,Jilin Province,130000 China;Department of General Surgery,Jilin Cancer Hospital,Changchun,Jilin Province,130000 China;Radiation Therapy Department,Jilin Cancer Hospital,Changchun,Jilin Province,130000 China)

机构地区：[1]吉林省肿瘤医院介入科,吉林长春130000 [2]吉林省肿瘤医院综合外科,吉林长春130000 [3]吉林省肿瘤医院放射治疗科,吉林长春130000

出　　处：《中外医疗》2023年第18期133-136,共4页China & Foreign Medical Treatment

基　　金：吉林省卫生健康科技能力提升项目(2021 LC132);吉林省科技发展计划项目(20190303168 SF)。

摘　　要：目的深入研究奥沙利铂+表柔比星介入治疗原发性肝癌的临床效果。方法回顾性分析2020年3月—2021年3月在吉林省肿瘤医院接受治疗的76例原发性肝癌患者的临床资料,根据治疗方法分为两组,各38例。研究组采用奥沙利铂+表柔比星治疗、参照组采用奥沙利铂+吉西他滨治疗。比较两组患者的临床疗效。结果治疗前,两组的肿瘤标志物比较,差异无统计学意义(P>0.05);治疗后,研究组的甲胎蛋白、缺氧诱导因子-1α、高尔基体蛋白低于参照组,差异有统计学意义(P<0.05)。治疗前,两组肝功能指标比较,差异无统计学意义(P>0.05);治疗后,研究组肝功能指标优于对照组,差异有统计学意义(P<0.05)。研究组的并发症发生率低于参照组,差异有统计学意义(P<0.05)。研究组的治疗总有效率(97.37%)高于参照组(65.79%),差异有统计学意义(χ^(2)=12.608,P<0.001)。结论给予患者奥沙利铂+表柔比星介入治疗,在控制肝癌疾病进展的同时,还能改善其肿瘤标志物等指标,不易引发一系列不良反应,安全性较高。Objective To thoroughly study the clinical effects of oxaliplatin+epirubicin intervention in the treatment of primary hepatocellular carcinoma.Methods Clinical data of 76 patients with primary liver cancer who received treatment in Jilin Cancer Hospital from March 2020 to March 2021 were retrospectively analyzed,and they were divided into two groups according to treatment methods,with 38 cases each.The study group was treated with oxaliplatin+epirubicin,and the reference group was treated with oxaliplatin+gemcitabine.The clinical efficacy of the two groups was compared.Results Before treatment,there was no statistically significant difference in tumor markers between the two groups(P>0.05).After treatment,the levels of alpha-fetoprotein,hypoxia-induced-factor-1αand golgi protein in the study group were lower than those in the reference group,and the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in liver function indexes between the two groups(P>0.05).After treatment,the liver function indexes of the study group were better than those of the control group,and the difference was statistically significant(P<0.05).The complication rate of the study group was lower than that of the reference group,and the difference was statistically significant(P<0.05).The total effective rate of the study group(97.37%)was higher than that of the reference group(65.79%),and the differences were statistically significant(χ^(2)=12.608,P<0.001).Conclusion Oxaliplatin+epirubicin interventional therapy can not only control the progression of liver cancer,but also improve tumor markers and other indicators,which is not easy to cause a series of adverse reactions and has high safety.

关 键 词：奥沙利铂 表柔比星 介入治疗 原发性肝癌 疗效 

分 类 号：R4[医药卫生—临床医学]